332 related articles for article (PubMed ID: 27671305)
41. Design, synthesis and biological activities of novel oxazolo[4,5-g]quinazolin-2(1H)-one derivatives as EGFR inhibitors.
Yin S; Zhou L; Lin J; Xue L; Zhang C
Eur J Med Chem; 2015 Aug; 101():462-75. PubMed ID: 26188620
[TBL] [Abstract][Full Text] [Related]
42. Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors.
Li SN; Xu YY; Gao JY; Yin HR; Zhang SL; Li HQ
Bioorg Med Chem; 2015 Jul; 23(13):3221-7. PubMed ID: 26003342
[TBL] [Abstract][Full Text] [Related]
43. Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors.
Wang Z; Wu X; Wang L; Zhang J; Liu J; Song Z; Tang Z
Bioorg Med Chem Lett; 2016 Jun; 26(11):2589-93. PubMed ID: 27118497
[TBL] [Abstract][Full Text] [Related]
44. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
[TBL] [Abstract][Full Text] [Related]
45. Optimization of gefitinib analogues with potent anticancer activity.
Yin KH; Hsieh YH; Sulake RS; Wang SP; Chao JI; Chen C
Bioorg Med Chem Lett; 2014 Nov; 24(22):5247-50. PubMed ID: 25305687
[TBL] [Abstract][Full Text] [Related]
46. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors.
Zhang H; Lu X; Zhang LR; Liu JJ; Yang XH; Wang XM; Zhu HL
Bioorg Med Chem; 2012 Feb; 20(4):1411-6. PubMed ID: 22277588
[TBL] [Abstract][Full Text] [Related]
47. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
48. Synthesis and in vitro biological evaluation of novel quinazoline derivatives.
Zhang Y; Zhang Y; Liu J; Chen L; Zhao L; Li B; Wang W
Bioorg Med Chem Lett; 2017 Apr; 27(7):1584-1587. PubMed ID: 28238614
[TBL] [Abstract][Full Text] [Related]
49. Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors.
Sun S; Zhang J; Wang N; Kong X; Fu F; Wang H; Yao J
Molecules; 2017 Dec; 23(1):. PubMed ID: 29295519
[TBL] [Abstract][Full Text] [Related]
50. EGFR inhibition studies by hybrid scaffolds for their activity against ovarian cancer.
Zhang F; Zhang H; Wang F
J BUON; 2016; 21(6):1482-1490. PubMed ID: 28039712
[TBL] [Abstract][Full Text] [Related]
51. Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold.
Chilin A; Conconi MT; Marzaro G; Guiotto A; Urbani L; Tonus F; Parnigotto P
J Med Chem; 2010 Feb; 53(4):1862-6. PubMed ID: 20095624
[TBL] [Abstract][Full Text] [Related]
52. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
[TBL] [Abstract][Full Text] [Related]
53. Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors.
Zhang L; Yang Y; Zhou H; Zheng Q; Li Y; Zheng S; Zhao S; Chen D; Fan C
Eur J Med Chem; 2015 Sep; 102():445-63. PubMed ID: 26310890
[TBL] [Abstract][Full Text] [Related]
54. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases.
Bridges AJ
Curr Med Chem; 1999 Sep; 6(9):825-43. PubMed ID: 10495354
[TBL] [Abstract][Full Text] [Related]
55. Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2.
Zhang HQ; Gong FH; Ye JQ; Zhang C; Yue XH; Li CG; Xu YG; Sun LP
Eur J Med Chem; 2017 Jan; 125():245-254. PubMed ID: 27688180
[TBL] [Abstract][Full Text] [Related]
56. New substituted 4-arylaminoquinazolines as potent inhibitors of breast tumor cell lines: in vitro and docking experiments.
de Oliveira AN; Bocca CC; Carvalho JE; Ruiz AL; Silva TP; Rittner R; Hoehr NF
Eur J Med Chem; 2010 Sep; 45(9):4339-42. PubMed ID: 20627376
[TBL] [Abstract][Full Text] [Related]
57. Antitumor activity, multitarget mechanisms, and molecular docking studies of quinazoline derivatives based on a benzenesulfonamide scaffold: Cell cycle analysis.
El-Azab AS; Abdel-Aziz AA; AlSaif NA; Alkahtani HM; Alanazi MM; Obaidullah AJ; Eskandrani RO; Alharbi A
Bioorg Chem; 2020 Nov; 104():104345. PubMed ID: 33142413
[TBL] [Abstract][Full Text] [Related]
58. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
Cai X; Zhai HX; Wang J; Forrester J; Qu H; Yin L; Lai CJ; Bao R; Qian C
J Med Chem; 2010 Mar; 53(5):2000-9. PubMed ID: 20143778
[TBL] [Abstract][Full Text] [Related]
59. Synthesis, and docking studies of some fused-quinazolines and quinazolines carrying biological active isatin moiety as cell-cycle inhibitors of breast cancer cell lines.
Radwan AA; Alanazi FK; Al-Dhfyan A
Drug Res (Stuttg); 2013 Mar; 63(3):129-36. PubMed ID: 23444171
[TBL] [Abstract][Full Text] [Related]
60. Design, synthesis and biological evaluation of some novel substituted quinazolines as antitumor agents.
Alanazi AM; Abdel-Aziz AA; Al-Suwaidan IA; Abdel-Hamide SG; Shawer TZ; El-Azab AS
Eur J Med Chem; 2014 May; 79():446-54. PubMed ID: 24763265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
